Navigation Links
Repligen Reports Second Quarter Fiscal Year 2011 Financial Results
Date:11/2/2010

d benefit from RG1068, a potential market opportunity of over $100 million.

RG2417 for Bipolar Disorder We have completed enrollment in our Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression. The study enrolled 175 patients at 29 clinical sites within the United States.  The primary objective of the Phase 2b study is to assess the efficacy of RG2417 on the symptoms of bipolar depression by demonstrating a greater improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) score of the patients receiving RG2417 when compared to placebo over an 8-week treatment period.  MADRS is a standardized, rater-administered scale, which has been used for numerous drug trials in bipolar disorder.  In addition, the study will assess the safety of RG2417 in patients with bipolar depression including, lack of induction of mania as measured by the Young's Mania Rating Scale.  Additional secondary and exploratory objectives include improvements in the Clinical Global Impression scale, difference in MADRS scores after 8 weeks of therapy, and responder rate as defined as percent of patients with an improvement in MADRS score of greater than 50% from baseline to week 8.  We expect to report top-line results of the Phase 2b study in the first quarter of 2011.  

This study is designed to confirm and extend the results of a Phase 2a study in which 6 weeks of treatment with RG2417 improved the symptoms of bipolar depression when compared to placebo as measured by the MADRS.  In the Phase 2a study, a lower placebo effect was observed in those patients with more numerous episodes of mania and depression experienced during their lifetime resulting in a higher apparent therapeutic effect of RG2417, which will also be assessed in the Phase 2b study.

Bipolar disorder is a chronic illness associated with substantial morbidity and mortality, ranking worldwide behind unipolar depre
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
2. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
3. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
4. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
5. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
6. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
7. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
8. Repligen to Present at the Cowen and Company 29th Annual Healthcare Conference Monday, March 16th, 2:25 p.m. EDT
9. Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results
10. Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
11. Repligen Announces Conference Call of First Quarter Fiscal Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)...  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property ... intellectual property, today announced a litigation update. ... Services Corp. et al. , Case No. 1:14-cv-00721-GBL-TCB, in ... of Virginia , the Court issued ... key claims in favor of the Defendants on the ...
(Date:7/1/2015)... and PARIS , July 1, ... Genective, key developer of biotech crops, today announce ... new generations of insect control traits. ... counter the realities of advancing insect resistance. We ... unique insect control technology with Genective,s capability in ...
(Date:7/1/2015)...  Axovant Sciences Ltd. (NYSE:  AXON), a leading ... dementia, today announced that the company will host ... p.m. EDT following its presentation of RVT-101 clinical ... (AAIC). The event will include ... Lawrence Friedhoff , Chief Development Officer, will present ...
(Date:7/1/2015)... ... July 01, 2015 , ... NEMA 4 (IP66) Medical ... new Medical Joysticks have an impermeable molecular barrier protection against bio-hazardous agents. ... that will increase healthcare worker safety and reduce financial costs. , CTI Electronics ...
Breaking Biology Technology:Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3AgBiome and Genective collaborate to create novel insect-resistant crops 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2
... July 8 Knowledge Enterprises, Inc.,and The ... of The,2007-2008 Orthopaedic Industry Annual Report, the ... data. The nearly 200,page Annual Report summarizes ... Joint Replacement, Fracture Repair, Arthroscopy/Soft,Tissue Repair, Spinal ...
... 8 Telik, Inc.,(Nasdaq: TELK ), today ... Chemistry Letters describing a novel class of small ... treatment for diabetes.,These unique compounds are the result ... optimize the original lead structure identified through,the application ...
... US-made bulk API, BATON ROUGE, La., ... (NYSE: ALB ), a leading global ... active pharmaceutical,ingredients (APIs), has signed a global ... As per the agreement, effective,immediately, Albemarle has ...
Cached Biology Technology:Knowledge Enterprises, Inc. and The Institute for Orthopaedics(TM) Release The 2007-2008 Orthopaedic Industry Annual Report 2Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters 2Albemarle Enters Ibuprofen Agreement with Dr. Reddy's 2Albemarle Enters Ibuprofen Agreement with Dr. Reddy's 3
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
(Date:6/24/2015)... SAN JOSE, Calif. , June 24, 2015 ... leading developer of human interface solutions, today announced ... fingerprint sensor to provide secure authentication for its ... Having recently reached more than 200 million shipments ... shipment with Sharp reinforces Synaptics, strength, scalability and ...
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... with the gradual acidification of the world,s oceans than previously ... escape climatic devastation. In new research published in the ... has identified a powerful internal mechanism that could enable some ... of a more acidic ocean. As humans release ever-larger ...
... , Radioactive iodine found by Dartmouth researchers in the ... a nuclear reactor,s explosion and meltdown half a world ... Department of Earth Science. The failure of the Fukushima ... earthquake and tsunami, was the largest nuclear disaster since ...
... be no accident when doctors observe how patients suffering ... more aggressive cancer. However, the new-found interaction between the ... A potential relationship between metastatic breast cancer and ... led researchers from the University of North Carolina at ...
Cached Biology News:Corals 'could survive a more acidic ocean' 2Corals 'could survive a more acidic ocean' 3Dartmouth scientists track radioactive iodine from Japan nuclear reactor meltdown 2Dartmouth scientists track radioactive iodine from Japan nuclear reactor meltdown 3Mechanism found connecting metastatic breast cancer and arthritis 2Mechanism found connecting metastatic breast cancer and arthritis 3
Goat polyclonal to Glucose Dehydrogenase ( Abpromise for all tested applications). Antigen: Glucose Dehydrogenase (Bacillus species)...
Phospho-CD18 (Ser756/Thr758/759) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Rabbit polyclonal to pCrosstide (HRP) ( Abpromise for all tested applications)....
Acetyl-Histone H2B (Lys20) Antibody...
Biology Products: